| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 38.46 | -0.32 (-0.83%) | 23.74 - 39.20 | 1.2 million (Below Avg) |
Market data as of 4:00PM 05/16/12. Quotes are delayed by at least 15 min.
| Open | 39.00 |
|---|---|
| Previous Close | 38.78 |
| Day's Range | 38.05 - 39.20 |
| Market Cap | 4.4B |
| Avg Volume (10 Day) | 1.4M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.66 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
No news headlines available for BMRN
| BMRN | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 11.92% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.45 | |
| LT Debt/Equity | 0.42 | |
| Earnings Yield | -- | |
| Price/Sales | 10.00 |
| Company | Last | Change |
|---|---|---|
| Amylin Pharmaceuticals Inc | 27.54 | +0.88% |
| Illumina Inc | 44.63 | +0.13% |
| Medivation Inc | 88.70 | +3.00% |
| Incyte Corp | 23.70 | +4.18% |
| Human Genome Sciences Inc | 14.25 | -2.13% |
Data is delayed by at least 15 min.